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Background: Epithelial-to mesenchymal transition (EMT) involves in metastasis, causing loss of epithelial polarity.
Metastasis is the major cause of carcinoma-induced death, but mechanisms are poorly understood. Here we identify
differentially expressed in adenocarcinoma of the lung-1 (DAL-1), a protein belongs to the membrane-associated
cytoskeleton protein 4.1 family, as an efficient suppressor of EMT in lung cancer.
Methods: The relationship between DAL-1 and EMT markers were analyzed by using immunohistochemistry in the
clinical lung cancer tissues. Quantitative real-time PCR and western blot were used to characterize the expression of
the EMT indicator mRNAs and proteins in DAL-1 overexpressed or knockdown cells. DAL-1 combined proteins were
assessed by co-immunoprecipitation.
Results: DAL-1 levels were strongly reduced even lost in lymph node metastasis and advanced pathological stage
of human lung carcinomas. Overexpression of DAL-1 altered the expression of numerous EMT markers, such as
E-cadherin, β-catenin Vimentin and N-cadherin expression, meanwhile changed the morphological shape of lung
cancer cells, and whereas silencing DAL-1 had an opposite effect. DAL-1 directly combined with E-cadherin
promoter and regulated its expression that could be the reason for impairing EMT and decreasing cell migration
and invasion. Strikingly, HSPA5 was found as DAL-1 direct binding protein.
Conclusions: These results suggest that tumor suppressor DAL-1 could also attenuate EMT and be important for
tumor metastasis in the early transformation process in lung cancer.
Keywords: Differentially expressed in adenocarcinoma of the lung-1, Epithelial-mesenchymal transition,
Lung cancer, E-cadherin, HSPA5Background
Lung cancer is the leading cause of cancer-related mortal-
ity worldwide [1]. The main cause of death is the invasion
and metastasis of tumor. EMT is the early event of lung
cancer metastasis which is characterized by a loss of cell-
cell adhesion and polarity, down-regulation of epithelial
markers, and acquisition of mesenchymal markers and
phenotype [2]. Thus, a better understanding of cellular
and molecular mechanisms leading to metastatic dissem-
ination of carcinoma cells is of utmost importance.
The human tumor suppressor gene DAL-1 was identi-
fied using Differential Display PCR as a gene whose* Correspondence: yajie.zhang@163.com
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unless otherwise stated.expression was lacking in non-small cell lung cancer
when compared with matched normal tissue [3]. Frequent
loss of DAL-1 in cervical cancer [4], laryngeal squamous
cell carcinoma [5], breast cancer [6] and esophageal squa-
mous cell carcinoma [7] suggested that DAL-1 could be a
tumor suppressor [8,9]. It has also been reported that loss
of DAL-1 expression and methylation of the DAL-1 pro-
moter are involved in development and progression of
NSCLC (Non small cell carcinoma), providing a possible
indicator of poor prognosis. Further studies demonstrated
DAL-1 contained FERM (protein 4.1-ezrin-radixin-moesin)
and SABD (spectrin-actin-binding domain) domain [10],
enable it links to the transmembrane protein and cytoskel-
eton. Consequently, DAL-1 was considered as membrane
associated protein contributing to cell shape, cell-cell andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pates in the organization of cytoskeleton [6,11]. E-cadherin
the key role in EMT and DAL-1 co-locate in the junction
part of cells, therefore, loss of DAL-1 may associate with
disruption of cell-cell adhesion, loss of polarity and cancer
metastasis.
Herein, the effect of DAL-1 on EMT was identified,
and its role on regulating EMT was illuminated in lung
cancer cell lines. In this paper, we showed that expres-
sion of DAL-1 was downregulated in metastatic tumours
and further identified DAL-1 as an EMT/metastasis
suppressor.
Material and methods
Tissue samples and cell lines
The paraffin-embedded tissues of 190 primary lung can-
cers and 163 matched corresponding tumor adjacent tis-
sues were obtained from patients who underwent primary
surgical treatment without systemic chemotherapy or
radiotherapy during the period 2005–2008. This project
had the informed consents from all the patients and was
approved by the First Affiliated Hospital of Guangzhou
Medical University and informed consent was taken from
all subjects. The average age of the patients at diagnosis
was 60.34 years, ranging from 25 to 82 years. These cases
included 77 squamous cell carcinomas (36 cases were well
or moderately differentiated, 41 cases were poor differenti-
ated), 85 adenocarcinomas (59 cases were well or moder-
ately differentiated, 26 cases were poor differentiated), 11
adeno-squamous carcinomas (moderately differentiated),
6 small cell carcinomas (poor differentiated), 5 large-cell
carcinomas (poor differentiated), 6 sarcomatoid carcin-
omas (poor differentiated). All samples were diagnosed
and classified according to the World Health Organization
grading system and the General Rules for Clinical.
The cell lines used in this study were purchased from
American Type Culture Collection (ATCC).
Plasmids and stable cell lines
Plasmid pcDNA3-DAL-1 containing full-length DAL-1
coding region was kindly provided by Dr. Philip
Washbourne (University of Oregon, USA). This plas-
mid was verified by DNA sequencing. The control vec-
tor pcDNA3 was purchased from Invitrogen (Grand
Island, NY, USA). Lipofectamine® LTX & Plus Reagent
(Invitrogen, Carlsbad, CA, USA) was used to transfect.
Transfected condition was pre-optimized using pEGFP-C1
(Clontec, Mountain View, CA, USA) to monitor the trans-
fection efficiency under inverted fluorescent microscopy.
To obtain stable transfectants, cells seeded in six-well
plates were transfected with 2.5 μg/well plasmids using
10 μl/well Lipofectamine®LTX Reagent and 2.5 μl/well
Plus Reagent. After 6 h incubation in serum and anti-
biotic free condition, the medium was replaced withRPMI 1640 containing 10% FBS, and the cells were cul-
tured for 48 h before submitting to a 2-week selection in
medium containing G418 (600 μg/ml).
Immunohistochemical staining
5-μm sections of paraffin-embedded tissues were treated
with pepsin or 30 min and blocked with BSA for 30 min
at room temperature. Tissue sections were then incu-
bated with antibodies to DAL-1, E-cadherin, Snail or
vimentin overnight at 4°C. Isotype control antibody
(Sigma-Aldrich) was used as a negative control. Each
slide was washed three times in TBS and incubated with
biotinylated anti–mouse IgG (Vector Laboratories) in a
humid chamber for 30 min. The positive cells were de-
tected using peroxidase-conjugated streptavidin (Vector
Laboratories) followed by 3′3-diaminobenzidine tetrahy-
drochloride (DAB; Vector Laboratories). The slides were
counterstained with hematoxylin.
Dual-luciferase reporter assay
The E-cadherin promoter (643 bp, from-450 to +193)
was cloned into pGL3-Enhancer vector (Promega). A549
cells were plated in 24-well plates at a density of 1 × 105
cells/well and grown overnight prior to transfection. The
cells were transfected with either DAL-1 plasmid or control
plasmid, and were co-transfected with pGL3-E-cadherin
promoter plasmid and pGL3-TK plasmid. Forty-eight hours
after transfection, the luciferase activities were analyzed by
the Dual-luciferase system according to the manufacturer’s
instruction (Promega). Three independent experiments
were performed.
Chromatin immunoprecipitation analysis
ChIP analysis was carried out as described previously
[12]. Briefly, Protein-DNA complexes were immunopre-
cipatited with DAL-1 antibody, with human IgG as a con-
trol, respectively. ChIP DNA was isolated with the
Qiaquick PCR Purification Kit (Qiagen). Subsequent qPCR
using 1⁄50 fraction of ChIP-enriched DNA and 100 nM
primers in a total volume of 20 μl was conducted to assess
the amount of DNA that had been precipitated. Standard
curves from 0.1-100 ng of sonicated genomic DNA were
also amplified by qPCR as a reference. DNA from these
samples was then subjected to PCR analysis. Primers sets
for E-cadherin promoter were 5′-gca gac tgg aag ggc gg-3′
and 5′-ggc agg cag ccc agc-3′.
Co-immunoprecipitation and mass spectrometric assay
and protein identification
Co-immunoprecipitation was performed using Pierce®
Co-IP kit (Thermo scientific, USA) following the manufac-
turer’s instruction. A549 cell lines stable tranfected either
DAL-1 or control were lysed in ice-cold IP Lysis/Wash
Buffer. After centrifugation at 13,000 g at 4°C for 10 min,
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control agarose resin before co-immunoprecipitation by
the resin coupled with goat anti-DAL-1 polyclonal anti-
body. The immunoprecipitate was isolated by the elu-
tion buffer and separated by 10% SDS-PAGE. Sliver
staining was used to detect the protein on the gel. The
protein bands were submitted for tryptic peptide mass
fingerprinting for identification by matrix-assisted laser
desorption/ionization time-of-flight/time of flight mass
spectrometry (MALDI-TOF/TOF-MS). Protein identifi-
cation was performed by searching protein databases of
Mascot (http://www.matrixscience.com).
Cells were lysed on ice for 30 min with a lysis buffer
(150 Mm NaCl, 25 mM Hepes, pH 7.4, 10 mM NaF,
5 mM MgCl2 1 mM EGTA, 1% Nonidet P-40, protease
inhibitors mixture:10 μg/ml aprotinin, 10 μg/ml leupep-
tin, 1 mM PMSF). Total lysates were precleared with
protein G-Sepharose for 1 h at 4°C and then immuno-
precipitated overnight with 2 μg of anti-Myc antibody
(Santa Cruz Biotechnology). Protein G-Sepharose was
then added, and the mixture was incubated for an add-
itional 1 h at 4°C. The beads were washed three times
with lysis buffer, followed by elution in Laemmli buffer.
The proteins were subjected to SDS-PAGE and Western
blotting according to standard procedures.
Migration and invasion assay
Cells were transfected with DAL-1, DAL-1 RNAi or
negative control using Transfection Agent (Ambion, TX,
USA) following manufacture’s protocol in 24-well plates.
24 h after transfection, Transwell migration assay and
Matrigel invasion assay were performed separately using
24-well Transwell inserts with 8 μm pore size (Corning
Costar Corp). For Transwell migration assay, 2 × 104
A549 or H460 cells suspended in 100 μl corresponding
culture medium without fetal bovine serum (FBS) were
loaded into the top chamber of transwell insert with
non-coated membrane. For Matrigel invasion assay, 5 ×
104 A549 or H460 cells were plated in 100 μl serum-free
medium in the upper Matrigel-coated chamber instead.
In both assays, the bottom chamber was containing
600 μl medium with 20% FBS. Cells were then allowed
to migrated or invaded for 12 h at 37°C. The cells that
migrated or invaded into the bottom chamber were
fixed, stained with 1% nuclear fast red staining solution,
visualized under phase contrast microscope and photo-
graphed. Total number of migrated or invaded cells was
counted by IPP (Image-Pro Plus 6.0) software. All exper-
iments were independently repeated at least three times.
Statistical analysis
Data were expressed as the mean ± SD for each group.
The difference between groups was analyzed using a fac-
torial model one-way analysis of variance. SPSS statisticalsoftware, version19.0 (Chicago, Illinois, USA) was used to
carry out all analyses and P less than 0.05 was considered
statistically significant. Each experiment was performed
in triplicate.
Results
DAL-1 is down-regulated in lung cancer tissues
Several kinds of lung cancer cell lines, including A549,
SPC-A1, PGC-L3, GLC-82, H1299, L78, and NCI-H460
were analyzed the DAL-1 mRNA and protein expression
levels. GLC-82 and NCI-H460 cell lines were positive
for DAL-1 mRNA and protein expression as indicated
by RT-PCR products at the expected size of 153 bp and
the specific protein binding band at the predicted size of
108 kDa. The endogenous DAL-1 expression had not
been found in other kinds of cell lines (Additional file 1).
To investigate the clinical importance of DAL-1 expres-
sion in lung cancer tissues and to explore its role on
EMT, the expression of E-cadherin, Vimentin and Snail
were examined on 190 cases of lung cancer tissues and
163 adjacent tissues samples by immunohistochemistry
analysis (Figure 1). Lower expression of DAL-1 was
found in tumor tissues compared with the normal adja-
cent tissues; higher expression of DAL-1 was found in
well differentiated lung cancer tissues compared with
poorly differentiated lung cancer tissues. Data present
from Table 1 showed that expression of E-cadherin was
lower (P < 0.05), whereas Vimentin and Snail protein
expression levels (P < 0.05) were higher in poorly dif-
ferentiated lung cancer tissues. Meanwhile, positive
staining of DAL-1 protein was preferentially observed
in tumors without lymph node metastasis (81/98,
82.6%) relative to those with lymph node metastasis
(52/92, 56.5%, P < 0.05). Positive DAL-1 staining was
significantly higher in tumors with pathological stages
I (69/83, 83.1%) than in those with stage II, III and IV
(77 of 107, 72.0%, P < 0.05).
Spearman rank correlation analysis was applied to
analyze the expression levels of DAL-1, E-cadherin,
Snail, vimentin in lung cancer tissues (Table 2). The ex-
pression of DAL-1 was positively correlated with E-
cadherin (r =0.710, P < 0.01), while negatively correlated
with Vimentin (r = −0.499, P < 0.01) and Snail (r = −0.318,
P < 0.01).
Based on our findings, the expression of DAL-1 is
downregulated in lung cancer compared to normal tissues
and significantly associated with disease progression, we
suggest that decreased expression of DAL-1 may occur in
the early stages of tumor development as well as be essen-
tial in maintaining tumorigenesis.
DAL-1 overexpression alters the expression of EMT markers
To verify whether DAL-1 is a crucial mediator of lung
cancer, we established A549 cell line stably overexpressing
Figure 1 Immunohistochemical staining on paraffin-embedded lung cancer tissue array sections. Tissue sections of lung cancer were
analyzed by IHC staining. The positive staining was shown in brown color. The sections were counterstained with hemotoxylin to show nuclei.
Representative images of DAL-1 staining is shown that lower expression of DAL-1 (A) and E-cadherin (B) could been seen in well- differentiated
adenocarcinoma, while positive expressions of snail (C) and Vimentin (D) were mainly localized in cytoplasm or nucleus of the serous lung cancer
cells. Magnification, ×200.
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trol cells through cell morphological observation. In
the initial characterization of these cells, we observed a
distinct morphological change in the cells overexpress-
ing DAL-1. The A549 cells expressing DAL-1 under-




+++ ++ + - P +++ ++ +
Diameter (cm)
>3 109 16 33 23 37
0.426
13 16 13
≤3 81 10 32 19 20 7 10 16
Differentiation
Well/mild differentiated 106 18 50 19 19
0.000
16 17 21
Poor differentiated 84 8 15 23 38 4 9 8
Lymph metastasis
N0 98 22 43 16 17
0.000
12 17 24
N1 92 4 22 26 40 8 9 5
Pathological stage
I 83 18 39 12 14
0.000
9 14 22
II 57 3 17 18 19 6 6 5
III 42 5 8 9 20 5 5 1
IV 8 0 1 3 4 0 1 1morphological shape, while the control A549 cells
(Vector/A549) appear fibroblast-like mesenchymal cell
morphological shape (Figure 2A).
Real-time quantitative PCR was used to assess the
mRNA levels of EMT markers. The details of primer se-
quences for target genes were showed in Additional file 2:clinical pathological characteristics
Vimentin Snail
- P +++ ++ + - P +++ ++ + - P
67
0.464
9 19 18 63
0.030
50 29 16 14
0.009
48 2 6 11 62 21 24 12 24
52
0.003
0 5 15 86
0.000
36 27 17 26
0.263
63 11 20 14 39 35 26 11 12
45
0.000
0 10 6 82
0.000
24 30 15 29
0.000
70 11 15 23 43 47 23 13 9
38
0.015
0 8 5 70
0.000
17 25 13 28
0.000
40 4 5 12 36 21 16 13 7
31 5 11 11 15 28 9 2 3
6 2 1 1 4 5 3 0 0
Table 2 Correlation of DAL-1, E-cadherin, vimentin, snail and clinical histology types
Group n
DAL-1 E-cadherin Vimentin Snail
+++ ++ + - P +++ ++ + - P +++ ++ + - P +++ ++ + - P
Tissue distribution
Lung cancer 190 26 65 42 57
0.000
20 26 29 115
0.000
11 25 29 125
0.000
71 53 28 38
0.000
Para-carcinoma tissue 163 86 59 4 14 81 54 8 20 0 0 0 163 28 25 14 96
Histology types
Squamous cell carcinoma 77 11 30 17 19
0.168
9 12 10 46
0.534
3 9 12 53
0.422
3 9 12 53
0.301
Small cell carcinoma 6 0 0 1 5 0 1 0 5 0 1 0 5 0 1 0 5
Adenocarcinoma 85 14 35 16 20 11 12 16 46 2 8 13 62 2 8 13 62
Large cell carcinoma 5 1 0 1 3 0 1 0 4 2 1 0 2 2 1 0 2
Adenosquamous carcinoma 11 0 0 5 6 0 0 2 9 3 2 4 2 3 2 4 2
Carcinoma sareomatodes 6 0 0 2 4 0 0 1 5 1 4 0 1 3 1 1 1
Figure 2 Effect of DAL-1 overexpression on morphology and EMT markers in A549 cells. Cells were stably transfected with pcDNA3-DAL-1
or pcDNA3 plasmid respectively. A, Morphological changes in DAL-1 overexpression cells, from spindle-like mesenchymal morphology into
epithelial morphology, by manifesting an increased cell-to-cell adhesion; B, Q-PCR analysis of the levels of EMT related markers after DAL-1stably
transfected with pcDNA3-DAL-1 plasmid; The levels of E-cadherin and β-catenin mRNAs were higher in the cells treated with the pcDNA3-DAL-1
plasmid than in the pcDNA3 treated cells (mock) or A549 cells (blank), but the level of Vimentin and N-cadherin mRNAs were lower. The data are
presented as the mean ± SD. n = 3, *P <0.05,#P <0.01. C, Western blot analysis of DAL-1 and EMT marker protein expression levels in A549 cells.
When the cells were transfected with the pcDNA3-DAL-1, the protein levels of E-cadherin and β-catenin increased while protein levels of
Vimentin N-cadherin were down-regulated.
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mRNAs were increased while Vimentin and N-cadherin
mRNAs were decreased in DAL-1 stable transfected cells
(*P <0.05, #P <0.01). Western blots also confirmed that
DAL-1 overexpression resulted in an increment in E-
cadherin and β-catenin expression and a reduction in
Vimentin and N-cadherin expression at the protein level
(Figure 2C).
We utilized the E-cadherin antibody and confocal mi-
croscopy to image E-cadherin expression in control and in
DAL-1-overexpressed A549 cells. Figure 3A demonstrated
that control A549 cells express relatively low levels of E-
cadherin, whereas DAL-1-overexpressed cells expressed a
great deal of E-cadherin localized in the plasma membrane.
In our previous studies, we found that DAL-1 af-
fected cell proliferation in lung cancer cells. Herein,
the role of DAL-1 in cell migration and invasion was
evaluated by the Matrigel-based transwell invasion
assay. The images showed that DAL-1 overexpression
inhibited cell migration (Figure 3B, a-b) and invasion
(Figure 3B, c-d) of A549 cells. The result of statistical
analysis was showed in Figure 3B, e (*P <0.05).Figure 3 DAL-1 attenuated cell migration and invasion in A549 cells.
described under “Experimental Procedures” and examined using confocal i
E-cadherin (green). Merged images are in the bottom of each panel. B, a-b
A549 cells. c-d, Matrigel cell invasion assay was performed after re-expressi
triplicate determinations, *P <0.05.DAL-1 deficiency alters the expression of EMT markers
In the present study, we have observed an apparent en-
dogenous expression of DAL-1 in NCI-H460 cells. To
address the role of DAL-1 in NCI-H460 non-small cell
lung cancer cell line, control and DAL-1 deficient cells
were developed using non-silencing shRNA as a control
and shRNA targeting DAL-1. As expected, DAL-1 knock-
down resulted in reduction of E-cadherin mRNA expres-
sion level whereas Vimentin and N-cadherin mRNA levels
were increased (Figure 4A). Similar results were obtained
at the protein levels utilizing western blotting (Figure 4B).
The Matrigel-based transwell invasion assay showed that
DAL-1 knockdown promoted cell migration (Figure 4C,
a-b) and invasion (Figure 4C, c-d) of A549 cells. Collect-
ively, these data suggest that DAL-1 could inhibit EMT in
lung cancer cell lines. The result of statistical analysis was
showed in Figure 4C, e (*P <0.05).
DAL-1 transcriptionally regulates E-cadherin
Although it had been confirmed that expression of DAL-1
had positive correlation with E-cadheirn, we asked whether
DAL-1 could regulate the activity of the E-cadherinA, mock and DAL-1 overexpressed A549 cells were stained as
mmunofluorescence microscopy, as follows: DAPI (blue, top panel) and
, Cell migration assay was performed after reintroduction of DAL-1 in
on of DAL-1 in A549 cells. e, The data are presented as mean ± SD for
Figure 4 DAL-1 deficiency alters the expression of EMT markers and metastasis ability. A, RNA extracts of control and DAL-1 knockdown
NCI-H460 cells were subjected to RT-PCR to determine the expression of target genes as indicated. B, The expression of EMT markers E-cadherin,
Vimentin and N-cadherin were measured in control and DAL-1 knockdown NCI-H460 cells by western blotting. C, Cell migration assay (a-b) and
invasion assay (c-d) were performed after knockdown of DAL-1 in NCI-H460 cells. e, The data are presented as mean ± SD for triplicate determinations,
*P <0.05.
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pcDNA3 vector or pcDNA3-DAL-1 plasmids were
transfected into A549 cells together with an E-cadherin
promoter. We examined the effect of DAL-1 overex-
pression or depletion on E-cadherin promoter lucifer-
ase reporter activity in the region of upstream 450 bp
to downstream 193 bp. Figure 5A demonstrated that E-
cadherin promoter activity was increased in DAL-1
overexpressed A549 cells comparing to the control cells
(*P <0.05). These finding suggest that DAL-1 may im-
pact on EMT through directly transcriptionally regulat-
ing E-cadherin.
To directly confirm the binding of E-cadherin pro-
moter to the endogenous DAL-1 protein in vivo, we
performed ChIP assays in NCI-H460 cells by using anti-
DAL-1 antibody. Figure 5B showed the schematic repre-
sentation of the E-cadherin regulational area. Two regions
were chosen to design the primers for qPCR. The result of
qPCR analysis demonstrated that E-cadherin promoter
(region 2) bound DAL-1 in vivo (Figure 5C). Different
primers were compounded and analyzed by PCR. The
PCR products were found using primers set spanning
E-cadherin but none with IgG control primers (Figure 5D).The results showed that DAL-1 bound to the region 2 of
E-cadherin promoter in vivo.HSPA5 as a direct associated protein to DAL-1
Previous investigation highlighted that DAL-1 located in
the lateral membrane of various epithelial cells, suggest-
ing it could participate in adherent junction. We per-
formed co-immunoprecipitation and mass spectrometric
assay to examine the binding proteins to DAL-1.
Figure 6A showed that the protein complex was co-
immunoprecipitated with the DAL-1 antibody-coupled
resin and followed SDS-PAGE for separation. Sliver
staining image showed that six differentially bands ap-
peared in the DAL-1 expression group while no spe-
cific band was observed at the same position of the
control group. The gel of the bands was sent to
MALDI TOF/TOF Mass Spectrometry for further ana-
lysis. Protein identification was finished by searching
the PMF (Peptide Mass Fingerprint). Mascot search re-
sults demonstrated the details of masss pectrometric
data (Additional files 3, 4, 5, 6, 7 and 8). The results from
Additional file 2: Table S2 showed five differentially
Figure 5 DAL-1 transcriptionally regulates E-cadherin. A, Dual-luciferase reporter assay showed that DAL-1 regulated E-caderin at the
transcriptional level. The data are presented as the mean ± SD. n = 6, *P <0.05. B, Schematic representation of the E-cadherin regulational area.
Two regions were chosen to design the primers for qPCR. C, The result DNA from chromatin immunoprecipitation assay was analyzed by qPCR.
D, Different primers were compounded and analyzed by PCR.
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beta chain and 14-3-3ε.
Further we investigated the association proteins by
using co-immunoprecipitation experiment, whether
they interacted with each other in lung cancer cells
were tested. As shown in Figure 6B, HSPA5 was co-
immunoprecipitated with DAL-1, whereas HSPA5 was
not detected when applied with control IgG. The re-
sults indicated that DAL-1 associated with HSPA5 dir-
ectly. Previous investigations have shown that HSPA5
may be an oncogene existing in cells. Moreover, we
verified that HSPA5 konckdown could interfere with
EMT by using RNA interference (RNAi) (Figure 6C).
HSPA5 knockdown resulted in reduction of snail and N-
cadherin expression levels whereas E-cadherin proein
level was increased (Figure 6D). Evidence of HSPA5
promoted the EMT process together with previous re-
sults, it would be important to note that DAL-1 might
inhibit HSPA5 then impact on EMT in lung cancer.
However, we have not yet identified the partner of
DAL-1 involved in this process and the mechanism
linked to HSPA5 remains to be investigated.Discussion
Tumor metastasis of is a complex multi-step and multi-
stage process [13,14]. The mortality of lung cancer is
often related to extensive metastasis [15,16]. During the
metastasis cascade, carcinoma cells often activate EMT to
underlie metastasis by promoting acquisition of migratory
and invasive abilities [17-19]. Therefore, understanding
the mechanisms inducing EMT is particularly important
for developing strategies for clinical therapy [20-22]. DAL-
1 was originally considered as a tumor growth suppressor
gene based on its downregulation in lung adenocarcinoma
[23,24]. Recent research reported that DAL-1 could sup-
press tumor metastasis [25].
As DAL-1 is associated with the cytoskeleton mole-
cules and can regulate the cellular functions in adhesion
and migration under physiological conditions [26,27], we
speculated that DAL-1 might suppress metastasis via inhi-
biting EMT. Forced DAL-1 expression, however, abolished
the metastatic capacity of a fibroblastoid, highly metastatic
human lung cancer cell line through reversal to an epithe-
lial phenotype. Loss of DAL-1 also predicted metastasis
and impaired survival in a lung cancer tissue arrays from
Figure 6 HSPA5 is the direct binding protein to DAL-1 which contributes positively to EMT in lung cancer. A, Co-immunoprecipitation
and mass spectrometric assay were performed to show the binding proteins to DAL-1. a, 4.1B; b, E-cadherin; c, HSPA5; d, P4HA1; e, Tubulin beta
chain; f, 14-3-3ε. B, Endogenous co-immunoprecipitation analysis conformed that HSPA5 was the direct binding protein to DAL-1. C, The function
of three designed HSPA5 RNA interference was determined by western blotting in A549 and NCI-H460 cells. D, The expression of EMT markers
E-cadherin, N-cadherin and snail were measured in control and HSPA5 knockdown A549 or NCI-H460 cells by western blotting.
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for human metastatic lung cancer. Since DAL-1 abolishes
metastatic capacity by re-inducing epithelial properties in
dedifferentiated tumour cells, it might also be a candidate
for gene therapy in metastatic cancer. DAL-1 overexpres-
sion altered the EMT markers expression, the expression
of E-cadherin and β-catenin were upregulated, and expres-
sion of vimentin and N-cadherin were downregulated.
Furthermore, inhibition of DAL-1 dramatically promoted
the migration and invasion abilities of lung cancer cells.
Our data together suggest that DAL-1 might contribute to
the development of EMT.
Studies to unravel possible mechanisms, how loss of
DAL-1 disturbs epithelial polarity with the outcome of
EMT, are hindered by the enormous complexity of these
processes. E-cadherin was observed to be upregulated
after DAL-1 reexpression. Consistent with previous re-
port, we confirmed that E-cadherin upregulation was
sufficient to inhibit EMT in lung cancer cells [28]. We
demonstrated that DAL-1 might increase the expression
of E-cadherin via transcriptional activating the E-
cadherin promoter. Our result of the dual-luciferasereporter assay and ChIP analysis identified that DAL-1
could bind E-cadherin promoter directly and increase
expression of E-cadherin as a transcriptional factor. Re-
cent study identified a putative NSL (nuclear localization
signal) in exon 12 of DAL-1 [29]. Interestingly, a casein
kinase II site, SAAE, is 26 amino acids upstream of the
NLS in exon 12. It has been reported that proteins contain-
ing an NLS often have casein kinase II site 10–30 amino
acids from the NLS [30]. The conformation of DAL-1
would be changed if the kinase site was phosphorylated,
and the NLS would be exposed to be identified, leading
DAL-1 into nuclear to act a role as transcriptional factor.
DAL-1 as an important component of membrane-
associated cytoskeleton was originally detected in cell-cell
junction part. DAL-1 contains some specific domains, in-
cluding SABD and FERM domains [31,32] which lead
DAL-1 function as a scaffold protein binding to the cell
membrane and connecting to the cytoskeleton [27,33,34].
This kind of structure is essential for the maintainance
of cell polarity and cell-cell adhesion [35,36]. Loss of
DAL-1 may cause impairing of this structure and result
in EMT development.
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immunoprecipitation assay. E-cadherin, β-tubulin, P4HA1,
14-3-3ε and HSPA5 had been found in the DAL-1 binding
complex. Previous research showed that DAL-1 interacted
with 14-3-3ε and contributed to cell apoptosis [37,38]. So
we performed endogenous co-immunoprecipitation experi-
ment to conform the direct interaction between DAL-1
and P4HA1, E-cadherin or HSPA5. P4HA1 as a Prolyl hy-
droxylase family member could upregulate E-cadherin ex-
pression via induce HIF degradation [39,40]. The results
showed that only HSPA5 was the combined protein to
DAL-1. Molecular chaperone HSPA5 was a key survival
factor in development and cancer [41]. HSPA5 may also be
important for tumor metastasis because it is elevated in
metastatic cancer cell lines, lymph node metastasis, and
knockdown of HSPA5 inhibits tumor cell invasion in vitro
and growth and metastasis in xenograft models [42,43].
The notable component of our work described here was
that HSPA5 interacted with DAL-1 directly. HSPA5 knock-
down could impact on EMT markers. Whether DAL-1
suppresses EMT via inhibiting HSPA5, further investiga-
tions will explore this mechanism.
Conclusions
In this study, we have demonstrated that the endogen-
ous expression of DAL-1 was negatively correlated with
the tumor pathological grading of clinical lung cancer sam-
ples. Further in vitro experiments have showed that DAL-1
reduced migration and invasion, transcriptional activated
E-cadherin promoter. Moreover, HSPA5 as a DAL-1 co-
precipitated protein contributed in EMT process. Based on
our observations and results reported by other groups, we
have proposed DAL-1 could attenuate EMT and be im-
portant for tumor metastasis in the early transformation
process of lung cancer. The experimental data and conclu-
sions in the present study furnish valuable information re-
garding the biological functions of DAL-1 and the possible
mechanism of the migration and invasion of lung tumor.
Thus, further studies will be focused on the molecular net-
work involved in the DAL-1 regulation on EMT.Additional files
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